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Alloimmunization is currently the most frequent adverse blood transfusion event. Whilst
completely matched donor blood would nullify the alloimmunization risk, this is practically
infeasible. Current matching strategies therefore aim at matching a limited number of
blood groups only, and have evolved over time by systematically including matching
strategies for those blood groups for which (serious) alloimmunization complications
most frequently occurred. An optimal matching strategy for controlling the risk of
alloimmunization however, would balance alloimmunization complications and costs
within the entire blood supply chain, whilst fulfilling all practical requirements and
limitations. In this article the outline of an integrated blood management model is
described and various potential challenges and prospects foreseen with the development
of such a model are discussed.
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1. INTRODUCTION
In a utopian world every blood transfusion would be handled like an organ transplant, whichmeans
that one would try to find a perfect match between donor and recipient. The reality however is that
completely matched donor blood is impossible in practice due to the abundance of blood group
antigens, costs associated with blood typing, and complications the logistics for such a scheme
would impose. As a consequence only a handful of blood group antigens are matched, posing
transfusion recipients at risk for alloimmunization and associated transfusion complications. An
ideal matching strategy would be one that minimizes the risk of alloimmunization, is cost-effective,
and fits within the practical limitations of the blood supply chain. In the past, matching strategies
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have been guided by the frequency of alloimmunization
incidents, without systematically considering all consequences
such strategies impose on the blood supply. Since a selected
matching strategy will either directly or indirectly affect the
entire blood supply chain (Figure 1), an integrated approach
is required. Such an approach would, for any particular
blood matching strategy, allow balancing the costs of donor
recruitment, donor typing, inventory management, blood
product logistics, patient blood typing, and alloimmunization
complications in transfusion recipients. Besides costs also the
effects of transfusion complications on patients health should be
taken into account. This article describes the outline of a generic
integrated blood management model, its components, their
interaction and potential complicating factors and limitations
currently foreseen for such a model.
We will first provide a description of all elements within
the blood transfusion chain that are relevant to such a blood
management model. Next we will describe how various elements
are combined into an integrated model. Finally, we will discuss
which challenges are foreseen with the implementation of
the model and potential prospects. Challenges will concern
knowledge required for shaping the modeling structure and
the availability of data for various model parameters. Not only
will the model guide the search for a rational choice of an
optimal matching strategy, it will create transparency for the
decision arena: the balance between costs and patient outcomes
will become explicit for whatever optimal decision is selected.
Secondly, by developing an integrated model, any blind spots in
knowledge regarding any of the elements of the decision model
will become visible and will have to be filled in.
FIGURE 1 | Schematic overview of blood type matching and its impact on the blood supply chain.
The elements identified for the integrated blood management
model are: the patient population, transfusion practice, pre-
disposition of transfusion complications, typing and matching
strategies, and the donor population. Note that as the patient
is the primary concern, it is the patient that should be the
starting point of the analysis. From there we will work our way
back through the blood transfusion chain toward the donor
population.
2. TRANSFUSED PATIENTS, EXPOSURE
AND TRANSFUSION COMPLICATIONS
Blood transfusion is one of the most common medical
procedures performed in hospitals. Despite its benefits, patients
exposed to red blood cell (RBC) alloantigens may produce
antibodies, which can cause acute or delayed hemolytic
transfusion reactions (HTR). In addition, upon pregnancy in
alloimmunized women, hemolytic disease of the fetus and new-
born (HDFN) may occur. Not all patients form antibodies after
RBC transfusion. According to current views, most are so-called
non-responders andwill never form antibodies despite numerous
transfusions. Others seem to have an increased immunization
risk and develop multiple antibodies after a few antigenic
exposures, these are referred to as the (hyper )responders (1). It
is currently not possible to prospectively identify patients that
will form antibodies. In the absence of phenotypic matching,
RBC alloimmunization risks vary between patient groups; it
occurs in less than 5% of all transfusion recipients, increases
to about 10–30% in patients with thalassemia, auto-immune
hemolytic anemia or myelodysplastic syndromes, and can be
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more than 50% in sickle cell anemia patients (2, 3). In addition,
patients with antibodies are at increased risk for additional
antibody development upon subsequent transfusions (4, 5).
During pregnancy, maternal RBC antibodies against paternal
inherited antigens can pose the child at risk for HDFN. Besides
anti-D, anti-E, anti-K, and anti-c are the most frequently
encountered antibodies with the potential to seriously complicate
pregnancy if the fetus carries the cognate antigen. The risk
for severe HDFN in these fetuses, requiring intra-uterine or
postnatal (exchange) transfusion, is estimated to be 12% for anti-
K, 8.5% for anti-c and about 1% for anti-E. While for anti-D,
administration of anti-D immunoglobulin (besides preventive D-
matching) has reduced the risk of D immunization from 15%
to 0.3%, such measures are not available or not always applied
for other antigens, which are in the majority of cases elicited by
previous transfusions (6).
The impact of transfusion reactions may vary widely, ranging
from serologic observations or mild symptomatic anemia only, to
life-threatening complications and death. It is obvious that with
increasing severity, costs of treatment will also increase, although
studies reporting on such associations and associated costs are
currently limited or completely lacking (7). Maximum benefits of
alloimmunization prevention can be obtained by administering
extended antigen matched blood to patients who have an a priori
high risk for alloimmunization. Therefore, unraveling genetic
and environmental conditions enhancing RBC immunization
would support preventive strategies. Although most studies
on this subject have been performed in sickle cell disease
(SCD) patients, factors such as age, sex, inflammatory status,
MHC class-II genotype, polymorphisms associated with immune
modulation and altered immune (regulatory) cells and disease
or therapy associated immunosuppression seem to influence the
immune response toward transfusion exposed alloantigens (1, 8–
13). Due to logistic constraints, elaborate preventive matching
based on a responder-profile is expected to be only feasible for
a small proportion of patients. Targeting patients with (chronic)
elective transfusions is likely to be feasible. Also, two recent
prospective studies showed that less than 50% of surgery patients,
who according to the local hospital pre-operative blood-ordering
schedule had a high transfusion risk, were actually transfused.
Extensive preventive matching as a routine policy is therefore
expected to require a substantial amount of additional work and
costs. Moreover, about 25% of patients required more than the
anticipated number of RBC units during surgery and extended
matched units were not readily available (14, 15).
As the blood management model is aiming to optimize
strategies for preventing HTRs, the risk of alloimmunization
in patients, its associated cost and health impact needs to
be explicated. The ongoing Dutch R-fact study in which the
predisposition for formation of antibodies is studied will allow
modeling the likelihood of antibody formation. This information,
combined with data on blood use for various patient groups,
which will be obtained from the Dutch PROTON study (in which
detailed transfusion data from a large number of hospitals are
combined in a Dutch Transfusion Datawarehouse), will provide
the information required to model the likelihood of HTRs in
various patient groups. Research on the cost and health impact
associated with HTRs will also be required to complete the model
for patient and health outcome of transfusion complications.
3. CURRENT MATCHING STRATEGIES IN
THE NETHERLANDS
In the Netherlands all RBC transfusions are compatible for ABO
and D antigens. Since 2011 the guideline for selection of RBC
units prescribes preventive matching for specific blood group
antigens for different patient subgroups. Since 2004 it has been
policy to select K-negative RBCs for women aged under 45, which
in 2011 was extended with matching for c and E. These measures
aim to prevent HDFN. In the updated guideline four patients
groups with a putative increased risk of alloimmunization were
defined, on grounds of either underlying disease, transfusion
frequency, or potential (hyper-)respondership. The four patient
groups concern (1) patients with autoimmune hemolytic disease;
(2) patients with myelodysplastic syndrome and (3) patients
with an immediate early antibody (IEA) against a clinically
relevant RBC antigen. For these three patient subgroups Rh
phenotype (CcDEe) and K compatible RBCs are selected. Finally,
the fourth group consists of patients with hemoglobinopathies
(SCD or thalassemia) for whom Rh phenotype, K and Fy(a)
compatible RBCs are selected, and whenever available, Jk(b), S
or s compatible RBCs. The recommended matching strategies
formulated in Dutch transfusion guidelines are summarized in
Table 1 (16).
Apart from these specific patient groups, patients in the
Netherlands are routinely tested for the presence of IEAs prior to
RBC transfusions. When IEAs are detected, both their specificity
and clinical importance are investigated. In case of a clinical
important IEAs it is essential to select donor erythrocytes
that are negative for corresponding antigens to prevent HTRs.
Furthermore, dependent on the matching strategy, it may be
required that donor erythrocytes are compatible with other
antigens of the patient (extended matched), to prevent the
formation of additional IEAs. Because antibodies may lose
detectability over time, accurate recording and accessibility of
patient antibody formation is of the utmost importance (17–19).
Besides in-hospital records, a national database is available in
theNetherlands (TRIX, Transfusion Register Irregular antibodies
and X(cross)-matching), in which hospitals register patients
with RBC antibodies and cross-match problems (20). This
system is accessed for the evanesced antibodies in all patients
TABLE 1 | Matching strategies for various patient groups as recommended in the
2011 Dutch Transfusion guideline.
Patient group Matching strategy
Sickle cell anemia and thalassemia Rh phenotype, K and Fy(a)
(and if available, Jk(b), S and s)
Autoimmune hemolytic anemia Rh phenotype and K
Myelodysplastic syndrome Rh phenotype and K
Alloimmunized with clinical important antibodies Rh phenotype and K
Woman of childbearing age c, E and K
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with a transfusion request to prevent re-exposure to the
cognate antigen. However, these registrations will not prevent
re-exposure due to an inadequate antibody follow-up after
transfusion.
The blood management model will have to accommodate
matching strategies currently implemented as well as various
extended matching strategies. The model should incorporate all
costs involved for various matching strategies considered (e.g.,
costs of personnel and materials used).
4. TYPING THE DONOR POPULATION
Different matching strategies will pose different requirements on
the availability of typed blood products. The required number
of typed blood products, the variation in its demand, and the
required service level (the probability of not being able to deliver
a requested typed blood product) will determine the number of
typed blood products that will have to be available in stock at
any time, and hence the level of typed donors. A large typed
donor population has the advantage that in most cases donor
erythrocytes can be selected directly from inventory, even when
blood products need to be typed negative for combinations of
antigens. However, there will always be a balance between the
additional efforts required to fulfill requirements for typed blood
products and extending the pool of elaborately typed donors.
5. DONOR RECRUITMENT
Transfusing matched blood is only feasible if there are enough
donors that are typed negative for specific (combinations
of) blood group antigens. For instance, many Blood Services
in Western countries have a structural shortage of Fy(a)-
neg, Fy(b)-neg, e-neg donors. This blood type is most
common in populations from Sub-Saharan Africa, of which
relatively few individuals are enrolled as blood donors (21).
In addition, in many countries a broad variety of ethnic
minority populations exist. Shifting immigration patterns and
mixing of these populations will increase the demand for rare
blood type combinations. A valuable side effect of recruiting
among minority groups is a potentially increase of donors for
HLA-matched substances of human origin, such as stem cells.
Blood Services therefore need to identify which specific ethnic
minority populations to focus on in terms of rare blood type
prevalence.
6. INTEGRATION
In the previous sections various elements of the blood transfusion
chain and their interdependencies were discussed (see Figure 1).
Each of these elements and their interactions need to be modeled
in order to allow evaluation of the impact of a particular
matching strategy on the transfusion risk of patients (i.e., acute
and delayed HTRs) and on other parts of the blood supply
chain (e.g., the availability of matched blood products, costs
of type and screen, storage, outdating, and targeted donor
recruitment). The main elements of the blood supply chain
and the associated sub-models describing various interactions
required for an integrated blood management model is depicted
in Figure 2.
The starting point for any evaluation is the blood matching
strategy, as this, in combination with the patient mix, will
determine the demand for particular blood products. Depending
on the matching strategy and patient mix (patient subgroups)
there will be a risk of antibody formation and subsequent risk for
adverse transfusion complications. Moreover, the combination
of patient mix and associated matching strategy will determine
the demand for typed blood products in the inventory. The
availability of typed blood products in the inventory is dependent
on the availability of typed blood donors, which again is
dependent on the efforts and requirements of targeted donor
recruitment.
The assessment of the transfusion complication risk requires
estimates of the likelihood of antibody formation and subsequent
transfusion reactions in patients given a particular matching
strategy. Such estimates should incorporate the transfusion
pattern and the ethnic (blood type) composition of various
patient sub-groups. Also, antigen specific estimates for the
likelihood of developing antibodies as well as for transfusion
complications are required. The likelihood of transfusion
complications in combination with cost and the health impact
FIGURE 2 | Main elements of the blood supply chain and associated sub-models of the blood management system.
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will allow estimation and subsequent balancing of the costs and
benefits from the matching strategy applied.
To enable matching blood for transfusion recipients antigen
and antibody profiles of patient subgroups have to be determined.
Next, compatible RBC units have to be selected from inventory.
Detailed information on blood use and the antigen profiles
per patient group allows assessment of the blood inventory
required to meet patient needs. This will be a description of the
required inventory both in terms of amount and composition
of RBCs in various stocks along the blood transfusion chain.
Blood product demand will show a stochastic behavior and a
realistic blood management model will therefore have to be
able to accommodate such random variations. Given the patient
mix, matching strategy and associated transfusion characteristics,
for any pre-specified acceptability rate for the unavailability of
(matched) blood products and inventory management strategy,
the required blood inventory size and composition can be
determined. The resulting costs and effects for the complete
blood transfusion chain (outdating, size of the inventory,
logistics, and material handling costs) can now be estimated.
Note that the unavailability of matched blood products will
impact the likelihood of transfusion complications in patients.
Therefore, optimization of the overall blood transfusion chain
will require a separate sub-optimization for the inventory
management strategy.
The availability of compatible RBC units required in the
inventory is directly linked to the availability of typed donors and
hence guides the typing strategy and targeted donor recruitment
efforts. The typing strategy will be aiming at fulfilling the
requirements for maintaining sufficient inventory levels, but this
will be dependent on the availability of specific antigen profiles
in the (typed) donor population. Whenever these are insufficient,
targeted donor recruitment efforts will have to ensure adequacy
of the desired antigen profiles in the un-typed donor population,
and ultimately those in the typed donor population. Estimates for
the costs of recruiting specific donor subgroups in order to ensure
a sufficient level of typed blood groups in the donor population
are required to estimate the costs for maintaining the required
inventory levels. Other than in the inventory management, which
is an in-line process, it is presumed that the required levels
of typed donors will be met by increasing donor recruitment
efforts.
7. DISCUSSION
In this article we discussed a conceptual framework for a
blood management model which allows optimization of blood
matching strategies. The model links various elements from the
blood transfusion chain to allow an assessment of the full impact
of any particular matching strategy. The approach is unique
in the sense that in the past matching strategies were guided
by the prevention of transfusions complications observed with
the administration of blood products, without consideration its
impact on the underlying blood supply process. In theory this
new approach seems sensible, however, in practice there will be
a number of complicating factors.
First of all, except for some specific patient subgroups
there is only limited evidence available on the effectiveness
of matching strategies for the prevention of transfusion
complications. Despite the fact that transfusion complications
are accurately analyzed, patient exposure is far more difficult
to ascertain. More evidence however has been gained for the
risks of alloimmunization in various patient cohorts in the
Netherlands in the ongoing Risk-Factors for alloimmunization
after red blood Cell Transfusion (R-FACT) study (22). This
concerted collaboration of several large hospitals will provide
the information required to model risk factors for some
patient subgroups. Also, looking back at the reduction of
transfusion complications after implementation of altered
matching strategies may support inference on its effectiveness.
However, this effect may also be confounded by transfusion
practice.
Another complicating factor is the impact of transfusion
complications on patients, as this may vary from serologic
observations or mild symptomatic anemia to life-threatening
complications and death. Not only are predictors for
predisposing factors lacking, but the impact of various levels
of transfusion complications on patient health (apart from
death) are not readily available, and neither are the associated
costs. Assessing costs of complications is complex as it requires
separation of the costs of patient treatment from costs of
complications which are confounded by definition. Similar
complications occur when estimating the impact on patient
health. Nonetheless, an increasing number of publications on
the impact of transfusion complications are becoming available
(23–25).
In most settings detailed information on transfusion practice
(number of transfused blood products for specific patient
subgroups and the variation herein) is lacking. In the
PROTON II study for a large number of Dutch hospitals
detailed information on blood transfusions administered to
patients is collected in one central datawarehouse (26).
These data consist not only of transfused products, but also
patient diagnosis and lab results. These data are indispensable
when modeling the logistics of the blood supply in general,
and for specific patient groups. Optimized inventory and
dispatching strategies can be developed for both hospital
and regional distribution centers and may be tailored to
specified matching strategies. Note that with data on blood
use the requirements and constraints for such models are
available.
For the assessment of the risk of transfusion reactions
(depending on the matching strategy) information on
historical exposure of patients to blood products is required
in order to assess the likelihood of antibody development.
Such data is at present only available at a large scale for
Denmark and Sweden where long term follow-up data on
transfused patients is recorded in the SCANDAT database
(27, 28). Such information may be used to estimate an
approximate risk of exposure to red blood cells in other
settings.
The development of an integrated blood management model
will increase transparency in costs and effects of selected
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matching strategies and is therefore -if applied- expected to
contribute to an improved efficiency in blood transfusion
practice.
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